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Abstract 
From several decades, some organophosphorus compounds specifically designed to alter 
biological systems were introduced on market as agrochemicals (ie glyphosate and glufosinate as 
herbicides). Nevertheless, it becomes necessary to find new compounds in order to counter plant 
resistances already observed with glyphosate. Fosmidomicyn and its N-acetyl analogues FR-
900098 were perceived as starting points for elaboration of new herbicide candidates, targeting 
the second enzyme of the non-mevalonate pathway in pla ts, the 1-deoxy-D-xylulose 5-
phosphate reductoisomerase (DOXP reductoisomerase or DXR). It is expected that the 
enhancement of bioactivity compared to the parent compounds, might be reached by insertion of 
two fluorine atoms close to the phosphonate functio. Indeed, the presence of both fluorine 
atoms could improve the lipophilicity, affect the pKa of the phosphonic acid function and then 
induce better activities. Herein, the synthesis of gem-difluorinated analogues of retrohydroxamic 
fosmidomycin and FR-900098-ester is reported using a radical addition mediated by a 
cobaloxime complex. 
 
Keywords: Fosmidomycin, phosphonate, hydroxamic acid, 1-deoxy-D-xylulose 5-phosphate 
reductoisomerase, DOXP reductoisomerase, DXR 
 
 
 
Introduction 
 
The world population is increasing and different estimations from United Nations planned for 
2050 a population ranging from 8 to 10.5 billion peo le. In order to supply sufficient food, the 
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crop productivity has to urgently increase, and elabor tion of powerful and ecocompatible new 
herbicides in absence of mammalian toxicity appears therefore a crucial issue. 
 The mevalonate-independent pathway of isoprenoid biosynthesis is widely found in many 
microorganisms1-4 as well as in higher plants,5,6 but it is missing in human, which uses 
mevalonate pathway for isoprenoid biosynthesis. The unique property of 1-deoxy-D-xylulose 5-
phosphate reductoisomerase (DXR), the second enzyme of th  DOXP pathway, can therefore be 
considered as a remarkable and safe target for the discovery of new herbicides. The 
fosmidomycin 1a isolated from Streptomyces lavendulae in the seventies, has been referenced as 
an inhibitor of the DXR enzyme,5,7 as well as N-acetyl homologue FR900098 1b,8,9 
fosmidomycin and FR900098 retrohydroxamic acids 1c-d10,11 and phosphate analogues, namely 
fosfoxacin 1e12 or acetyl analogue 1f12 (Figure 1). Fosmidomycin 1a has been positively 
evaluated for the treatment of uncomplicated falciprum malaria in combination with 
clindamycin,13-15 as well as for its herbicide activities, by use alone in combination with 
commercial triazine or urea herbicides.16 Nevertheless, to date and despite these promising 
results, fosmidomycin has not been reached on the market neither as antimalarial drug nor as 
herbicide agent. 
 In the case of the phosphate derivative 1e and preferentially 1f, their respective activity 
clearly revealed stronger than the fosmidomycin on Sy echocystis DXR.12 These results could be 
directly attributed to the phosphate function. However, the intrinsic stability of phosphate group 
in biological media was questionable and clearly constituted its main drawback for a possible 
herbicide development. From a bioisostere approach, Van Calenbergh,17 replaced oxygen atom 
by a monofluoromethylene group (CHF) and thus, two m nofluorinated to FR900098 and to 
retrohydroxamic-FR900098 analogues were prepared. Both structures displayed that they were, 
in vitro, more potent than fosmidomycin and FR900098 towards P. Falciparum strain K1, and 
the antimalarial activity in an in vivo mouse model exceeded those of 1b.17 
 By comparison to monofluoromethylene group, the difluoromethylene group (CF2) exhibits 
also steric and electronic properties close to oxygen.18-21 As a consequence of this equivalence, 
the pKa values of the difluorophosphonate are relatively similar to the phosphate,19-21 and it 
might be considered as equivalent to the acidic character of phosphoric group of natural substrate 
2. Moreover, the replacement of phosphate bond (HO2P( )O-R) by a phosphonate linkage 
(HO2P(O)CF2-R) should increase chemical stability towards phosatase, favouring a better 
bioavailability.22 Finally, the DXR inhibitor incorporating difluoromethylene group, could have a 
higher lipophilic character,23 allowing potentially a better integration in plants. Therefore, it 
became obvious that an α,α'-difluorophosphonate group should advantageously replace the 
phosphate group of 1f, and preparation of compounds 3 and 4, analogues to FR-900098 1b and 
parent molecule 1c, were thus planned to enhance activity of DXR inhibitor for an herbicide 
application (Figure 1). 
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Figure 1. DXR enzyme inhibitors 1a-f referenced and the natural substrate 2. Targeted gem-
difluorophosphonate 3 and retrohydroxamic–fosmidomycin 4 as 1b-c analogues. 
 
 
Results and Discussion 
 
It was expected that fluoro analogues of fosmidomycin, and retrohydroxamic fosmidomycin 3 
and 4 would be accessible from a same key precursor, the bromodifluoromethylphosphonate 7. 
Furthermore, reactions of phosphonate 7 with an appropriate alkene had to afford fluoro 
intermediates 5 or 6, which then would be transformed into hydroxamate by modification of the 
terminal alkene 5 or ester function from 6 (Scheme 1). 
 
 
 
Scheme 1. Retrosynthetic pathway. 
 
 In the literature, several strategies were described for the introduction of difluoromethylene 
group linked to a phosphonate.18 The most efficient pathway to produce quantitatively 7, has 
been to use the Arbusov reaction according to Davisson method, of triethyl phosphite and 
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difluorodibromomethane.24 Furthermore, the transformation of bromodifluoromethyl-
phosphonate 7 into nucleophilic Grignard or heterocuprate reagents and their reaction with allyl 
bromide were explored. Unfortunately, none of these reactions were successful to produce allyl 
difluoromethylphosphonate 5.
 Another strategy developed by Hu,25 using a bimetallic redox system constituted by 
cobaloxime(III)/Zn and reported to initiate the radical addition of per(poly)fluoroalkyl bromides 
to electron deficient alkenes, has been used with success producing allyl phosphonate 525 and the 
phosphonobutyrate 625 in 50% and 32% yields respectively (Scheme 2). Nevertheless, as 
mentioned by Hu, during the process, difluoromethylp osphonate 8 was formed as major side 
product, and in the case of 5, all trials to entirely remove it were unsuccessful. F rthermore, the 
mixture of 5 and 8 has been used for preparation of N-phosphonohydroxamate ester 12.
 
 
 
Scheme 2. Preparation of intermediates 5 and 6 by Hu’s method. 
 
 The preparation of N-phosphonohydroxamate ester 12 was accomplished through an 
ozonolysis of the alkene 5 applying the Chambers’s procedure.26 Due to its low stability, 
aldehyde 9 had to be promptly used for the next step, and its transformation by a reductive 
amination, using sodium cyanoborohydride in acidic conditions,27 afforded the O-
benzylhydroxylamino phosphonate 10 in 68% yield. Finally, the acylation was performed in 
dichloromethane using acetyl chloride and triethylamine as a base. Difluoromethyl hydroxamate 
11 was obtained in 86% yield. The benzyl group was cleaved using hydrogen and palladium 
hydroxide as catalyst, giving the difluoromethylphosphonate 12 analogue of FR-900098-ester 
(95% yield). The hydrolysis of the phosphonate ester using trimethylsilyl bromide,28,29 followed 
by methanolysis at room temperature, did not afford pure phosphonic acid 3. Otherwise, another 
attempt by acidolysis of 12 and neutralization, followed by N-acetylation also revealed not 
convincing for a clean access to phosphonic acid 3 (Scheme 3). 
 Contrary to 3, the synthesis of the difluorofosmidomycin analogue 4 has been achieved 
without difficulty. Firstly, the hydrolysis of the ester 6 under acidic conditions produced the 
corresponding carboxylic acid 13 in nearly quantitative yield. After chlorination and reaction 
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with O-benzylhydroxylamine, the protected hydroxamic acid 14, was isolated in 80% yield. 
From compound 14, benzyl group was removed quantitatively by hydrogenolysis to give 15. The 
final step of the synthesis was the deprotection of the corresponding phosphonate into 
phosphonic acid 4 (75% yield), using 10 equivalents of trimethylsilyl bromide followed by a 
methanolysis at room temperature (Scheme 4). 
 
 
 
Scheme 3. Synthesis of gem-difluoro 12, analogue of FR-900098-ester. 
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Scheme 4. Synthesis of gem-difluorinated retrohydroxamic acid triethylammonium salt 4. 
 
 
Conclusions 
 
In conclusion, using difluorobromomethylphosphonate as a key building block, we performed an 
efficient synthesis of new gem-difluorinated analogues of retrohydroxamic fosmidomycin and 
retrohydroxamic-FR-900098-ester 4 and 12. Both fluorinated fosmidomycin analogues 4 and 12 
were not active on the biological tests for determination of herbicide activity. 
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Experimental Section 
 
General. All air and/or water sensitive reactions were carried out under nitrogen atmosphere. 
The solvents were dried using standard methods, distilled and stored under nitrogen. Reactions 
were monitored by 31P NMR using DMSO–d6 as internal references. Purifications by column 
chromatography were performed on silica gel (Merck 60 AC. 35–70µm). 
Unless otherwise specified, NMR spectra were recorded on a BRUKER Ultra shield 400 plus 
instrument at 161.99 MHz for 31P, 376.50 MHz for 19F, 400.13 MHz for 1H and 100.61 MHz for 
13C. The spectrometer used for low and high resolution mass spectra was electrospray ionization 
(ESI) WATERS Micromass Q-Tof spectrometer with as internal reference H3PO4 (0.1 % in 
water/acetonitrile, 1:1). 
The diethyl (bromodifluoromethyl)phosphonate 7, was prepared according to procedure 
described by Davisson.24 The diethyl 1,1-difluoro-3-butenylphosphonate 525,30,31 and methyl 4-
(diethoxyphosphinyl)-4,4-difluorobutyrate 625 were synthesized using procedure reported by 
Hu.25 Diethyl (1,1-difluoro-3-oxopropyl)phosphonate 926 was accessible applying Chambers’s 
procedure.26 
 
Diethyl (3-(benzyloxyamino)-1,1-difluoropropyl)phosphonate 10. In a 500 mL two-necked 
flask were introduced diethyl 1,1-difluoro-3-oxopropylphosphonate 9 (3.0 g, 13 mmol), O-
benzyl-hydroxylamine (1.6 g, 13 mmol) and methanol (10 mL). The reaction mixture was stirred 
for 1h at room temperature. After addition of methanol (190 mL) the mixture was treated 
portionwise with sodium cyanoborohydride (2.45 g, 39 mmol) over 30 min. Then, aqueous 
hydrochloric acid (13 mL, 37%) was added over 40 min under ice cooling. The mixture was 
allowed to warm up to room temperature and sodium cyanoborohydride (0.57 g, 9.1 mmol) was 
added. The reaction mixture was stirred at room temperature over 2 h. The solution was 
concentrated and treated with aqueous potassium hydroxide (10%) until pH basic. The product 
was extracted with ethyl acetate (3 × 150 mL), the organic layers were combined, dried over 
MgSO4 and concentrated under vacuum. A purification by column chromatography on silica gel 
with heptane/EtOAc/EtOH as eluent (100:0:0 to 60:36:4) gave 10 as a yellow liquid (3.0 g, 
68%). 31P NMR (CDCl3): δ 6.90 (t, J 107.5 Hz). 
19F NMR (CDCl3): δ –111.08 (d, J 107.9 Hz). 
1H NMR (CDCl3): δ 1.39 (t, 6H, J 7.0 Hz, CH3), 2.30-2.46 (m, 2H, CH2), 3.24 (t, 2H, J 7.2 Hz, 
CH2), 4.24–4.33 (m, 4H, P(O)OCH2), 4.71 (s, 2H, PhCH2), 5.69 (broad s, 1H, NH), 7.28–7.34 
(m, 5H, Ph). 13C NMR (CDCl3): δ 16.4 (d, J 5.1 Hz, CH3, 2 C), 32.2 (td, J 20.5 Hz and 14.6 Hz, 
CH2, 1 C), 44.4 (q, J 5.4 Hz, NCH2, 1 C), 64.5 (d, J 6.6 Hz, P(O)OCH2, 2 C), 76.2 (s, PhCH2, 1 
C), 120.5 (td, J 259.8 Hz and 215.9 Hz, CF2, 1C), 127.9 (s, CHar, 1 C), 128.4 (s, CHar, 2 C), 
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128.4 (s, CHar, 2 C), 137.7 (s, Car, 1 C). HRMS (m/z) calcd for C14H23F2NO4P: 338.1333. 
Found: 338.1327. 
Diethyl (3-(N-(benzyloxy)acetamido)-1,1-difluoropropyl)phosphonate 11. In a 100 mL two-
necked flask were introduced diethyl (3-(benzyloxyamino)-1,1-difluoropropyl)phosphonate 10 
(1.2 g, 3.6 mmol), triethylamine (0.58 mL, 4.2 mmol) and CH2Cl2 (30 mL). The reaction mixture 
was cooled to 0°C and acetyl chloride (0.30 mL, 4.2 mmol) was added dropwise. The mixture 
was stirred overnight at room temperature. Then, water (20 mL) was poured on and the reaction 
mixture was extracted with CH2Cl2 (2 × 50 mL). The organic layers were combined, dried over 
MgSO4 and concentrated under vacuum. Purification by column chromatography on silica gel 
with as eluent a mixture of heptane/EtOAc/EtOH (100:0:0 to 50:45:5) gave 11 (1.2 g, 86%). 31P 
NMR (CDCl3): δ 6.51 (t, J 107.0 Hz). 
19F NMR (CDCl3): δ –112.34 (d, J 106.7 Hz). 
1H NMR 
(CDCl3): δ 1.39 (t, 6H, 
3JHH 7.0 Hz, CH3), 2.10 (s, 3H, CH3), 2.40–2.47 (m, 2H, CH2), 3.93 (t, 
2H, 3JHH 7.5 Hz, NCH2), 4.24–4.33 (m, 4H, OCH2), 4.85 (s, 2H, PhCH2), 7.35–7.43 (m, 5H, Ph). 
13C NMR (CDCl3): δ 16.4 (d, J 5.9 Hz, CH3, 2 C), 20.6 (s, CH3, 1 C), 30.8 (q, J 18.3 Hz, CH2, 1 
C), 38.5 (s, CH2, 1 C), 64.6 (d, J 6.6 Hz, OCH2, 2 C), 76.5 (s, PhCH2, 1 C), 119.8 (td, J 259.8 Hz 
and 215.9 Hz, CF2, 1 C), 128.8 (s, CHar, 2 C), 129.1 (s, CHar, 1 C), 129.3 (s, CHar, 2 C), 134.2 
(s, Car, 1 C), 172.0 (s, C(O), 1 C). HRMS (m/z) calcd for C16H25F2NO5P: 380.1438. Found: 
380.1448. 
Diethyl (1,1-difluoro-3-(N-hydroxyacetamido)propyl)phosphonate 12. In a Schlenck tube 
under nitrogen were introduced palladium dihydroxide on charcoal (150 mg, 10%) and 11 (1.5 g, 
4.0 mmol) in degassed ethanol (100 mL). The reaction mixture was stirred vigorously under a 
hydrogen atmosphere at room temperature for 12 h. The reaction mixture was filtered on a celite 
pad and the filtrate was concentrated under vacuum to afford 12 as yellow liquid (1.1 g, 95%). 
31P NMR (CD3OD): δ 5.17 (t, J 108.0 Hz). 
19F NMR (CD3OD): δ –114.98 (d, J 107.9 Hz). 
1H 
NMR (CD3OD): δ 1.39 (td, 6H, J 7.1 Hz and 0.5 Hz, CH3), 2.10 (s, 3H, CH3), 2.35–2.45 (m, 2H, 
CH2), 3.87 (t, 2H, J 7.7 Hz, NCH2), 4.26–4.34 (m, 4H, OCH2). 
13C NMR (CD3OD): δ 14.9 (d, J 
5.1 Hz, CH3, 2 C), 18.5 (s, CH3, 1 C), 30.3 (td, J 20.5 Hz and 14.6 Hz, CH2, 1 C), 40.2 (q, J 5.8 
Hz, NCH2, 1 C), 64.6 (d, J 7.3 Hz, OCH2, 2 C), 119.4 (td, J 259.1 Hz and 218.8 Hz, CF2, 1 C), 
172.2 (s, C(O), 1 C). HRMS (m/z) calcd for C9H19F2NO5P: 290.0969, found: 290.0974. 
4-Diethoxyphosphinyl-4,4-difluorobutanoic acid 13. In a 100 mL two-necked flask were 
introduced methyl 4-(diethoxyphosphinyl)-4,4-difluorobutyrate 6 (4.5 g, 16.4 mmol) and acetone 
(40 mL), followed by a slow addition of hydrochloric acid solution (22 mL, 6 M). The resulting 
mixture was stirred under reflux for 45 min. The acetone was removed under vacuum and the 
product was extracted with diethyl ether (3 × 100 mL). The organic layers were combined, dried 
over MgSO4 and concentrated under vacuum to give 13 as a colorless liquid (4.0 g, 94%). 
31P 
NMR (101.25 MHz, CDCl3): δ 6.47 (t, J 107.9 Hz). 
19F NMR (235.33 MHz, MeOD): δ – 114.01 
(d, J 108.2 Hz). 1H NMR (250 MHz, CDCl3): δ 1.38 (t, 6H, J 7.1 Hz, CH3), 2.32–2.69 (m, 4H, 
CH2CH2), 4.22–4.34 (m, 4H, OCH2), 8.64 (broad s, 1H, OH). 
13C NMR (CDCl3): δ 16.3 (d, J 5.9 
Hz, CH3, 2 C), 25.8 (q, J 5.1 Hz, CH2, 1 C), 29.2 (td, J 21.2 Hz and 16.0 Hz, CH2, 1 C), 64.9 (d, J 
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6.6 Hz, CH2, 2 C), 119.8 (td, J 259.8 Hz and 217.4 Hz, CF2, 1 C), 175.96 (s, C(O), 1 C). HRMS 
(m/z) calcd for C8H16F2O5P: 261.0703, found: 261.0722. 
Diethyl (4-(benzyloxyamino)-1,1-difluoro-4-oxobutyl)phosphonate 14. In a 250 mL two-
necked flask were introduced 4-diethylphosphonyl-4,4-difluorobutyric acid (13, 4.0 g, 15.4 
mmol) and CH2Cl2 (100 mL). The mixture was cooled at 0 °C and thionyl chloride (2.25 mL, 
30.8 mmol) was slowly added. The resulting mixture was stirred at room temperature for 4 h, 
then concentrated under vacuum and evaporated twicewith dry toluene (2 × 20 mL). The acyl 
chloride was used directly without further purification. In a 250 mL two-necked flask were 
successively introduced O-benzyl hydroxylamine (2.27 g, 18.4 mmol), CH2Cl2 (150 mL) and 
triethylamine (2.6 mL, 18.7 mmol). A solution of 4-diethoxyphosphinyl-4,4-difluorobutyric acid 
chloride (15.4 mmol) in CH2Cl2 (50 mL) was added dropwise. The mixture was stirred at room 
temperature overnight. Then, water (100 mL) was poured on and the product was extracted with 
CH2Cl2 (3 × 150 mL). The organic layers were combined, dried over MgSO4 and concentrated 
under vacuum. The residue was purified by column chromatography on silica gel with as eluent a 
mixture of heptane/EtOAc/EtOH (100:0:0 to 40:54:6) affording 14 as yellow liquid (4.5 g, 80%). 
31P NMR (CD3OD): δ 5.34 (t, J 109.0 Hz). 
19F NMR (CD3OD): δ –115.66 (d, J 109.2 Hz). 
1H 
NMR (CD3OD): δ 1.38 (t, 6H, J 7.1 Hz, CH3), 2.30-2.50 (m, 4H, CH2CH2), 4.24–4.34 (m, 4H, 
OCH2), 4.84 (s, 2H, PhCH2), 7.35–7.45 (m, 5H, Ph). 
13C NMR (CDCl3): δ 16.4 (d, J 5.1 Hz, 
CH3, 2 C), 24.9 (s, CH2, 1 C), 29.7 (q, J 19.0 Hz, CH2, 1 C), 64.7 (s, OCH2, 2 C), 78.1 (s, 
PhCH2, 1 C), 120.1 (td, J 259.8 Hz and 215.9 Hz, CF2, 1 C), 128.5 (s, CHar, 2 C), 128.6 (s, 
CHar, 1 C), 129.1 (s, CHar, 2 C), 135.4 (s, Car, 1 C), 168.9 (s, C(O), 1 C). HRMS (m/z) calcd for 
C15H23F2NO5P: 366.1282. Found: 366.1281. 
Diethyl (1,1-difluoro-4-(hydroxyamino)-4-oxobutyl)phosphonate 15. Proceeding as for 12, 
compound 15 was obtained from 14 as yellow liquid (1.1g, 98%). 31P NMR (CDCl3): δ 6.51 (t, J 
108.0 Hz). 19F NMR (CDCl3): δ –111.86 (d, J 107.9 Hz). 
1H NMR (CDCl3): δ 1.31 (t, 6H, J 7.0 
Hz, CH3), 2.2–2.5 (m, 4H, CH2-CH2), 4.15–4.25 (m, 4H, OCH2), 8.70 (broad s, 0.8H), 9.87 
(broad s, 0.8H). 13C NMR (CDCl3): δ 16.3 (d, J 5.1 Hz, CH3, 2 C), 24.5 (CH2, 1 C), 29.7 (q, J 
19.3 Hz, CH2, 1 C), 65.0 (d, J 6.6 Hz, OCH2, 2 C), 120.1 (td, J 259.8 Hz and 216.6 Hz, CF2, 1 
C), 169.4 (s, C(O), 1 C). HRMS (m/z) calcd for C8H17F2NO5P: 276.0812. Found: 276.0809. 
Triethylammonium (1,1-difluoro-4-(hydroxyamino)-4-oxobutyl)phosphonate 4. In a 50 mL 
three-necked flask were introduced 15 (1 mmol) and CH2Cl2 (10 mL). The mixture was stirred in 
an ice bath (T = 0°C) and trimethylsilylbromide (1.3 mL, 10 mmol) was added. The reaction 
mixture was stirred at room temperature for 14 h and concentrated to dryness under vacuum. 
Methanol (10 mL) was added and the resulting mixture was stirred at room temperature for 2 h 
and then concentrated under vacuum. The crude was dissolved in methanol (10 mL) and 
triethylamine (1.4 mL, 10 mmol) was added slowly. The solvent was removed under vacuum. 
The crude was dissolved in water (50 mL) and the suspension filtered off. The aqueous layer was 
washed with chloroform (3 × 50 mL). After concentration under vacuum, the salt 4 was obtained 
as a colorless gum (240 mg, 75%). 31P NMR (D2O): δ 4.75 (t, J 95.1 Hz); 
19F NMR (D2O): δ –
113.50 (d, J 95.2 Hz). 1H NMR (D2O): δ 1.14 (t, 9H, J 7.3 Hz, CH3), 2.1-2.3 (m, 2H, CH2), 2.46 
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(t, 2H, J 7.3 Hz, CH2C(O)), 3.06 (q, J 7.3 Hz, 6H, 
5CH2). 
13C NMR (D2O): δ 8.2 (s, CH3, 3 C), 
27.1 (q, J 5.4 Hz, CH2C(O), 1 C), 29.4 (td, J 21.2 Hz, and 14.6 Hz, CH2, 1 C), 46.6 (s, NCH2, 3 
C), 122.0 (td, J 257.6 Hz and 196.9 Hz, CF2, 1 C), 178.8 (s, C(O), 1 C). HRMS (m/z) calcd for 
C4H9F2NO5P: 220.0186. Found 220.0191. 
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